Trials
8 active
10 in total · 9 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Central Precocious Puberty
- Main trialPhase 4
- “A Single-Arm, Open-Label, Multicenter, Prospective Clinical Study to Evaluate the Effectiveness and Safety of Leuprorelin 1-Month (4-Week) Formulation Administered for 24 Months in Children with Central Precocious Puberty”In the company’s words, NCT07710430 on ClinicalTrials.gov
Other drugs for Central Precocious Puberty
- -endoxifenAtossa Therapeutics, Inc. · Phase 2
Coming up1
- 30 Aug 2029Phase 4 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials10
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Recruiting | 30 Aug 2029 | A Study of Leuprorelin 1-Month (4-Week) Formulation in Children With Central Precocious Puberty | |
| Phase 3Authorised | not given | Metastasis-directed therapy for oligorecurrent prostate cancer : A randomized phase III trial. | |
| Phase 3Ended | not given | The AGAINST-PLD; An investigator-driven, randomized, open label clinical trial assessing efficacy of leuprorelin to halt disease progression in PLD | |
| Phase 3Authorised | not given | EORTC-2238-GUCG: Intermittent Androgen deprivation Therapy in the era of AR pathway inhibitors; a phase 3 pragmatic randomized trial (DE-ESCALATE) | |
| Phase 3Authorised | not given | ADOPT; Androgen Deprivation therapy for Oligo-recurrent Prostate cancer in addition to radioTherapy | |
| Phase 3Authorised | not given | GETUG 20 : Phase III randomised trial to evaluate the benefit of adjuvant hormonal treatment with leuprorelin acetate (Eligard® 45 mg) for 24 months after radical prostatectomy in patients with high risk of recurrence | |
| Phase 4Authorised | not given | Assisted reproductive technology (ART) and pregnancy outcomes in women with adenomyosis (internal endometriosis) according to stimulation protocol in relation to immunological and endometrial features: a prospective, randomized study | |
| Phase 3Authorised | not given | Short versus long-term androgen deprivation therapy combined with salvage radiotherapy in prostate cancer patients with biochemical recurrence after prostatectomy: a multicentre phase III randomised controlled trial | |
| Phase 2Ended | not given | EvaluatioN of High-Intensity Focused Ultrasound (HIFU) Hemi-ablation and short-term AndrogeN deprivation therapy Combination to Enhance prostate control for intermediate risk localized prostate cancer: the ENHANCE prospective feasibility trial | |
| Phase 3Authorised | not given | OPTIMA YOUNG : Optimal Personalized Treatment of early breast cancer using Multi-parameter Analysis : focus on YOUNGer women |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026